FINWIRES · TerminalLIVE
FINWIRES

午盤漲幅最大的股票

By

-- Sagimet Biosciences (SGMT) 週一宣布，已完成約 2,920 萬股的承銷發行，每股定價 6 美元，預計籌集約 1.75 億美元，用於資助其臨床試驗。 受此消息提振，Sagimet Biosciences (SGMT) 股價飆漲 43%，盤中交易量從日均約 51.6 萬股暴增至超過 4,520 萬股。 Veradermics (MANE) 週一宣布，其針對輕度至中度男性脫髮患者的口服藥物 VDPHL01 的 2/3 期臨床試驗 A 部分已達到所有主要終點和所有關鍵次要終點，且具有「高度」統計意義。 受此消息提振，Veradermics (MANE) 股價上漲 32%，盤中交易量超過 250 萬股，而日均交易量約為 44.6 萬股。 Oruka Therapeutics (ORKA) 股價週一飆升 16%，此前該公司宣布，在針對中重度斑塊狀銀屑病的 2a 期臨床試驗中，接受 ORKA-001 治療的患者中，近 64% 在第 16 週達到了主要終點——皮膚完全清除。 當日成交量超過 510 萬股，而每日平均成交量約為 76 萬股。

Price: $8.36, Change: $+2.50, Percent Change: +42.58%

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP
Research

Research Alert: CFRA Maintains Sell Opinion On Shares Of P&g

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $7 to $136, based on 19.5x our FY 26 EPS estimate and below the company's five-year average forward P/E multiple of 23.6x, reflecting our view of increased competition, higher commodity prices, and ambitious growth targets. We maintain our FY 26 and FY 27 EPS estimates of $6.96 and $7.27, respectively. P&G posted normalized FQ3 EPS of $1.59 vs. $1.54 in the year prior and $0.03 above consensus estimates. Net sales rose to $21.2B, representing a 7% increase that included a 4%-pt tailwind from FX. Organic sales advanced 3%, driven equally by a 2% increase in volume and 1% improvement in pricing, while mix remained neutral. Profitability metrics came under pressure during the quarter as gross margin contracted by 150 bps to 49.5%. On a core basis, gross margin declined 100 bps to 50.0%, impacted by 180 bps of unfavorable mix, 100 bps of reinvestments, 50 bps of higher tariff costs, and 10 bps of unfavorable commodity costs. We remain at Sell on shares.

$PG